CLOs on the Move


 
BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.bhei.com
  • 265 Franklin St
    Boston, MA USA 02110
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Cychem

Cychem is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EZ-MED

EZ-MED is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

growve

Growve is a company that specializes in acquiring, operating, and growing world class brands in the supplements & active nutrition, beauty & personal care, home & leisure, lifestyle foods, and pet care verticals.

Goodness Growth

Goodness Growth Holdings, Inc. is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. Today, the Company is licensed to grow, process, and/or distribute cannabis in four markets and operates 14 dispensaries in three states.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.